KR880005936A - 저분자량 글루코스아미노글리칸의 조절된 제조방법 - Google Patents
저분자량 글루코스아미노글리칸의 조절된 제조방법 Download PDFInfo
- Publication number
- KR880005936A KR880005936A KR1019870013216A KR870013216A KR880005936A KR 880005936 A KR880005936 A KR 880005936A KR 1019870013216 A KR1019870013216 A KR 1019870013216A KR 870013216 A KR870013216 A KR 870013216A KR 880005936 A KR880005936 A KR 880005936A
- Authority
- KR
- South Korea
- Prior art keywords
- molecular weight
- heparin
- solution
- sulfate
- carried out
- Prior art date
Links
- 238000002360 preparation method Methods 0.000 title claims 2
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 claims description 5
- 229920000669 heparin Polymers 0.000 claims description 4
- 229960002897 heparin Drugs 0.000 claims description 4
- 238000000034 method Methods 0.000 claims 13
- 239000000243 solution Substances 0.000 claims 6
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims 5
- 239000008103 glucose Substances 0.000 claims 5
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 claims 3
- 230000005251 gamma ray Effects 0.000 claims 3
- 239000011347 resin Substances 0.000 claims 3
- 229920005989 resin Polymers 0.000 claims 3
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 claims 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims 2
- 238000001816 cooling Methods 0.000 claims 2
- 239000000203 mixture Substances 0.000 claims 2
- 230000014508 negative regulation of coagulation Effects 0.000 claims 2
- 239000008194 pharmaceutical composition Substances 0.000 claims 2
- 239000002994 raw material Substances 0.000 claims 2
- 238000001223 reverse osmosis Methods 0.000 claims 2
- 150000003839 salts Chemical class 0.000 claims 2
- KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 claims 1
- 229920001287 Chondroitin sulfate Polymers 0.000 claims 1
- 102000009123 Fibrin Human genes 0.000 claims 1
- 108010073385 Fibrin Proteins 0.000 claims 1
- BWGVNKXGVNDBDI-UHFFFAOYSA-N Fibrin monomer Chemical compound CNC(=O)CNC(=O)CN BWGVNKXGVNDBDI-UHFFFAOYSA-N 0.000 claims 1
- 229920002683 Glycosaminoglycan Polymers 0.000 claims 1
- 229920002971 Heparan sulfate Polymers 0.000 claims 1
- 102000004032 Heparin Cofactor II Human genes 0.000 claims 1
- 108090000481 Heparin Cofactor II Proteins 0.000 claims 1
- 229920000288 Keratan sulfate Polymers 0.000 claims 1
- 238000010521 absorption reaction Methods 0.000 claims 1
- 239000012190 activator Substances 0.000 claims 1
- 229920000615 alginic acid Polymers 0.000 claims 1
- 229960001126 alginic acid Drugs 0.000 claims 1
- 235000010443 alginic acid Nutrition 0.000 claims 1
- 239000000783 alginic acid Substances 0.000 claims 1
- 150000004781 alginic acids Chemical class 0.000 claims 1
- 239000012670 alkaline solution Substances 0.000 claims 1
- 230000001858 anti-Xa Effects 0.000 claims 1
- 230000003171 anti-complementary effect Effects 0.000 claims 1
- 230000003110 anti-inflammatory effect Effects 0.000 claims 1
- 230000002785 anti-thrombosis Effects 0.000 claims 1
- 239000003146 anticoagulant agent Substances 0.000 claims 1
- 239000007864 aqueous solution Substances 0.000 claims 1
- 230000003139 buffering effect Effects 0.000 claims 1
- 239000002775 capsule Substances 0.000 claims 1
- 125000002091 cationic group Chemical group 0.000 claims 1
- 229940094517 chondroitin 4-sulfate Drugs 0.000 claims 1
- KXKPYJOVDUMHGS-OSRGNVMNSA-N chondroitin sulfate Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](OS(O)(=O)=O)[C@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](C(O)=O)O1 KXKPYJOVDUMHGS-OSRGNVMNSA-N 0.000 claims 1
- 239000006196 drop Substances 0.000 claims 1
- 239000003889 eye drop Substances 0.000 claims 1
- 229940012356 eye drops Drugs 0.000 claims 1
- 229950003499 fibrin Drugs 0.000 claims 1
- 238000009472 formulation Methods 0.000 claims 1
- 238000005194 fractionation Methods 0.000 claims 1
- 150000004676 glycans Chemical class 0.000 claims 1
- 229920002674 hyaluronan Polymers 0.000 claims 1
- 229960003160 hyaluronic acid Drugs 0.000 claims 1
- 238000010255 intramuscular injection Methods 0.000 claims 1
- 239000007927 intramuscular injection Substances 0.000 claims 1
- -1 intravenous Substances 0.000 claims 1
- 238000010253 intravenous injection Methods 0.000 claims 1
- KXCLCNHUUKTANI-RBIYJLQWSA-N keratan Chemical compound CC(=O)N[C@@H]1[C@@H](O)C[C@@H](COS(O)(=O)=O)O[C@H]1O[C@@H]1[C@@H](O)[C@H](O[C@@H]2[C@H](O[C@@H](O[C@H]3[C@H]([C@@H](COS(O)(=O)=O)O[C@@H](O)[C@@H]3O)O)[C@H](NC(C)=O)[C@H]2O)COS(O)(=O)=O)O[C@H](COS(O)(=O)=O)[C@@H]1O KXCLCNHUUKTANI-RBIYJLQWSA-N 0.000 claims 1
- 238000006386 neutralization reaction Methods 0.000 claims 1
- 230000003472 neutralizing effect Effects 0.000 claims 1
- 229910052757 nitrogen Inorganic materials 0.000 claims 1
- 239000002674 ointment Substances 0.000 claims 1
- 238000000746 purification Methods 0.000 claims 1
- 239000007787 solid Substances 0.000 claims 1
- 239000002904 solvent Substances 0.000 claims 1
- 238000007920 subcutaneous administration Methods 0.000 claims 1
- 238000010254 subcutaneous injection Methods 0.000 claims 1
- 239000007929 subcutaneous injection Substances 0.000 claims 1
- 239000000126 substance Substances 0.000 claims 1
- 238000013268 sustained release Methods 0.000 claims 1
- 239000012730 sustained-release form Substances 0.000 claims 1
- 239000003826 tablet Substances 0.000 claims 1
- 238000005314 correlation function Methods 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
- A61K31/726—Glycosaminoglycans, i.e. mucopolysaccharides
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
- B01J19/00—Chemical, physical or physico-chemical processes in general; Their relevant apparatus
- B01J19/08—Processes employing the direct application of electric or wave energy, or particle radiation; Apparatus therefor
- B01J19/081—Processes employing the direct application of electric or wave energy, or particle radiation; Apparatus therefor employing particle radiation or gamma-radiation
- B01J19/082—Gamma-radiation only
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08B—POLYSACCHARIDES; DERIVATIVES THEREOF
- C08B37/00—Preparation of polysaccharides not provided for in groups C08B1/00 - C08B35/00; Derivatives thereof
- C08B37/006—Heteroglycans, i.e. polysaccharides having more than one sugar residue in the main chain in either alternating or less regular sequence; Gellans; Succinoglycans; Arabinogalactans; Tragacanth or gum tragacanth or traganth from Astragalus; Gum Karaya from Sterculia urens; Gum Ghatti from Anogeissus latifolia; Derivatives thereof
- C08B37/0063—Glycosaminoglycans or mucopolysaccharides, e.g. keratan sulfate; Derivatives thereof, e.g. fucoidan
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08B—POLYSACCHARIDES; DERIVATIVES THEREOF
- C08B37/00—Preparation of polysaccharides not provided for in groups C08B1/00 - C08B35/00; Derivatives thereof
- C08B37/006—Heteroglycans, i.e. polysaccharides having more than one sugar residue in the main chain in either alternating or less regular sequence; Gellans; Succinoglycans; Arabinogalactans; Tragacanth or gum tragacanth or traganth from Astragalus; Gum Karaya from Sterculia urens; Gum Ghatti from Anogeissus latifolia; Derivatives thereof
- C08B37/0063—Glycosaminoglycans or mucopolysaccharides, e.g. keratan sulfate; Derivatives thereof, e.g. fucoidan
- C08B37/0075—Heparin; Heparan sulfate; Derivatives thereof, e.g. heparosan; Purification or extraction methods thereof
- C08B37/0078—Degradation products
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Molecular Biology (AREA)
- Polymers & Plastics (AREA)
- Materials Engineering (AREA)
- Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- Veterinary Medicine (AREA)
- Toxicology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Dermatology (AREA)
- Polysaccharides And Polysaccharide Derivatives (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Saccharide Compounds (AREA)
- Peptides Or Proteins (AREA)
- Medicinal Preparation (AREA)
Abstract
내용 없음
Description
본 내용은 요부공개 건이므로 전문내용을 수록하지 않았음
제1도는 조사(단위:Megarad)에 따른 헤파린 활성도(USP)의 변화 관계 데이타를 보여준다.
제2도는 조사(단위:Megarad)에 따른 분자량의 변화 관계 데이타를 보여준다.
제3도는 M.W 대 Mrad의 통계적 상관 함수를 보여준다.
Claims (15)
- 고체상태 또는 용액 형태의 통상적인 고분자량 글리코스아미노글리칸을 하나의 조사단계와 다음 단계 사이에 냉각 간격을 둔 연속적인 조사단계에 의해 정지 또는 바람직하게 동적 상으로 공급되는 2.5Mrad 내지 27Mrad·범위내 적용량의 직진 감마선으로 처리한 다음, 수득된 용액에서 고분자량 분획을 제거하기 위해 화학적으로 분류하고, 역삼투에 의해 바람직한 기저분획을 정제하고, 세파크릴 또는 다른 형태의 수지 컬럼을 통해 정제된 용액을 추가로 분류하고, 수득된 분획을 양이온성 수지로 옮긴 다음, 이들을 알칼리성 용액으로 중화시키고 동결건조 시킴을 특징으로 하는 저분자량 글루코스아미노글리칸의 조절된 제조방법.
- 제1항에 있어서, 원물질로서 사용된 상기 글루코스아미노글리칸이 100 내지 250μ/mg USP항응고 활성을 갖는 헤파린인 방법.
- 제1항에 있어서, 원물질로서 사용되는 상기의 통상적인 글루코스아미노글리칸이 저속 헤파린, 고속 헤파린, 헤파린 설페이트, 콘드로이틴-4-설페이트, 콘드로이틴-6-설페이트, 케라탄 설페이트, 하이알루론산, 알긴산 또는 메소글리칸 단독으로 또는 여러 성분들의 혼합물로 구성됨을 특징으로 하는 방법.
- 제1항에 있어서, 상기 감마선 처리를 pH 2 내지 8로 완충시키는 것이 가능한 수용액 중의 글루코스아미노 글리칸에 대해 수행함을 특징으로 하는 방법.
- 제1항에 있어서, 상기 감마선 처리를 탈공기화 되고 질소로 정화된 1 내지 30%W/V 농도로 글루코스아미노글리칸 수용액상에 대해 수행함을 특징으로 하는 방법.
- 제1항에 있어서, 상기 연속적인 조사단계의 각 단계가 2 내지 3Mrad의 적용량을 제공함을 특징으로 하는 방법.
- 제1항에 있어서, 냉각 간격이 하나의 조사단계의 종결과 다음 단계의 시작 사이임을 특징으로 하는 방법.
- 제1항에 있어서, 상기 감마선 처리를 20 내지 55℃, 바람직하게는 20 내지 40℃의 온도에서 수행함을 특징으로 하는 방법.
- 제1항에 있어서, 상기 화학적 분류를 메탄올, 에탄올 및 아세톤과 같은 용매 10 내지 30%W/V의 양으로 처리함으로써 2 내지 5%W/V 수용액에서 수행함을 특징으로 하는 방법.
- 제1항에 있어서, 기저 분획의 정제를, 저분자량 분획 및 염 성분이 모두 제거될 때까지 500 컷오프를 갖는 역삼투에 의해 수행함을 특징으로 하는 방법.
- 제1항에 있어서, 정제된 용액의 추가의 분류를 세라크릴, 세파텍스 50 또는 다른 형태의 수지 컬럼에서 수행함을 특징으로 하는 방법.
- 제1항에 있어서, 상기 중화를 알칼리성 Na, Ca, K, Mg 또는 Li 용액으로 수행하는 방법.
- 1000 내지 35,000 돌턴 분자량을 가지며 10 내지 250μ/㎎ USP의 항응고 활성도 및 1 내지 15 이상의 항 -Xa/APTT비를 갖는 제1항 내지 제12항 중 어느 한 항에 따라 수득된 글루코스아미노글리칸.
- 항혈전성제, 피브린 용해제, 소염제, 항보체제 또는 항아테로젠제 및 헤파린 보조인자 II활성화제로서 사용하기 위한 약제학적 조성물을 제조하기 위한 Na, Ca, K, Mg 또는 Li염 형태의 제13항에 따른 글루코스 아미노글리칸의 용도.
- 제14항에 있어서, 상기한 약제학적 조성물을 정제, 캡슐, 점적약, 경구투여용 용액, 안약, 연고, 정맥내, 피하 및 근육내 주사용 물약 및 서방출 피하흡수용 특정 제제의 형태로 제조함을 특징으로 하는 글루코스아미노글리칸의 용도.※ 참고사항 : 최초출원 내용에 의하여 공개하는 것임.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| IT22434/A/86 | 1986-11-24 | ||
| IT8622434A IT1213384B (it) | 1986-11-24 | 1986-11-24 | Processo per la preparazione controllata di gilcosaminoglicani a basso peso molecolare. |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| KR880005936A true KR880005936A (ko) | 1988-07-21 |
Family
ID=11196265
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1019870013216A KR880005936A (ko) | 1986-11-24 | 1987-11-24 | 저분자량 글루코스아미노글리칸의 조절된 제조방법 |
Country Status (15)
| Country | Link |
|---|---|
| US (1) | US4987222A (ko) |
| EP (1) | EP0269937B1 (ko) |
| JP (1) | JPS63213502A (ko) |
| KR (1) | KR880005936A (ko) |
| AT (1) | ATE60924T1 (ko) |
| AU (1) | AU603622B2 (ko) |
| CA (1) | CA1305134C (ko) |
| DE (1) | DE3768074D1 (ko) |
| DK (1) | DK602387A (ko) |
| ES (1) | ES2020993B3 (ko) |
| FI (1) | FI88045C (ko) |
| GR (1) | GR3001670T3 (ko) |
| IT (1) | IT1213384B (ko) |
| NO (1) | NO874777L (ko) |
| PT (1) | PT86191B (ko) |
Families Citing this family (36)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH0748559B2 (ja) * | 1988-11-30 | 1995-05-24 | シャープ株式会社 | 半導体装置 |
| EP0421508B1 (en) * | 1989-10-04 | 1993-12-15 | Akzo Nobel N.V. | Sulphated glycosaminoglycuronan with antithrombotic activity |
| IT1240615B (it) * | 1990-04-03 | 1993-12-17 | Mediolanum Farmaceutici Spa | Impiego del dermatan solfato nella prevenzione e terapia dell'invecchiamento cerebrale e degli stati di deficit funzionale del sistema nervoso centrale |
| FR2663639B1 (fr) * | 1990-06-26 | 1994-03-18 | Rhone Poulenc Sante | Melanges de polysaccharides de bas poids moleculaires procede de preparation et utilisation. |
| USRE38743E1 (en) | 1990-06-26 | 2005-06-14 | Aventis Pharma S.A. | Mixtures of particular LMW heparinic polysaccharides for the prophylaxis/treatment of acute thrombotic events |
| US5230832A (en) * | 1991-01-24 | 1993-07-27 | Brandeis University | Galactomannan-agarose binary gel for nucleic acid electrophoresis |
| IT1256236B (it) * | 1992-12-23 | 1995-11-29 | Mediolanum Farmaceutici Srl | Oligosaccaridi aventi attivita' biologica e procedimento per la loro preparazione di glicosaminoglicani |
| FR2718025B1 (fr) * | 1994-03-30 | 1996-06-21 | Paris Val Marne Universite | Médicament et composition pharmaceutique pour le traitement des lésions du système nerveux. |
| US5585361A (en) * | 1994-06-07 | 1996-12-17 | Genzyme Corporation | Methods for the inhibition of platelet adherence and aggregation |
| EP0795560B1 (en) * | 1994-12-01 | 2003-12-10 | Seikagaku Corporation | Keratan sulfate oligosaccharide fraction and drug containing the same |
| DE19646901A1 (de) * | 1996-11-13 | 1998-05-14 | Helmut Prof Dr Heusinger | Verfahren zum Herstellen von Abbauprodukten polymerer Glycosaminoglycane mittels Ultraschall |
| DE29900874U1 (de) | 1999-01-20 | 1999-07-22 | Knoll AG, 67061 Ludwigshafen | Organprotektive Lösungen |
| DE19920688A1 (de) * | 1999-05-05 | 2000-11-23 | Manfred Kuhn | Radiolytisch modifizierte Heteropolysaccharide |
| IT1312107B1 (it) * | 1999-05-14 | 2002-04-04 | Umberto Cornelli | Glicosaminoglicani aventi peso molecolare medio di 2400 d atti altrattamento della demenza senile |
| AU1502700A (en) * | 1999-11-30 | 2001-06-12 | Dalian Yaweite Biology Engineering Co., Ltd. | The alginate having low molecular weight, methods of manufacturing it and its use |
| US6383344B1 (en) * | 2000-07-19 | 2002-05-07 | Genzyme Corporation | Molecular weight reduction of polymer using irradiation treatment |
| US6969705B2 (en) * | 2000-07-21 | 2005-11-29 | Aventis Pharma S.A. | Compositions of polysaccharides derived from heparin, their preparation and pharmaceutical compositions containing them |
| US6610810B2 (en) | 2001-03-13 | 2003-08-26 | Glyn Owen Phillips | Biopolymers obtained by solid state irradiation in an unsaturated gaseous atmosphere |
| US7618652B2 (en) * | 2001-03-23 | 2009-11-17 | Hepmarin As | Glycosaminoglycan anticoagulants derived from fish |
| EP1344781A1 (en) * | 2002-03-12 | 2003-09-17 | Laboratori Derivati Organici S.P.A. | Process for the depolymerization of glycosaminoglycanes and products obtained therefrom |
| ITMI20021372A1 (it) * | 2002-06-21 | 2003-12-22 | Derivati Organici Lab | Processo per la depolimerizzazione fisica dei glicosamminogliacani e prodotti da esso ottenuti |
| US20040171819A1 (en) * | 2002-10-10 | 2004-09-02 | Aventis Pharma S.A. | Mixtures of polysaccharides derived from heparin, their preparation and pharmaceutical compositions containing them |
| EP1440683A1 (de) * | 2003-01-23 | 2004-07-28 | Cognis France S.A. | Verwendung von Oligoglucosaminen in kosmetischen oder dermatologischen Zubereitungen |
| US20040161476A1 (en) * | 2003-02-19 | 2004-08-19 | Hahn Sungtack Samuel | Cystitis treatment with high dose chondroitin sulfate |
| US7956046B2 (en) * | 2003-07-24 | 2011-06-07 | Aventis Pharma S.A. | Oligosaccharide mixtures derived from heparin, preparation thereof and pharmaceutical compositions containing them |
| EP1524276A1 (en) * | 2003-10-16 | 2005-04-20 | Laboratori Derivati Organici S.P.A. | Multistep process for the physical depolymerization of heparin and products obtained therefrom |
| US20050154196A1 (en) * | 2004-01-13 | 2005-07-14 | Seikagaku Corporation | Process for producing sugar in which molecular weight is lowered |
| US20050261241A1 (en) * | 2004-05-19 | 2005-11-24 | Celsus Biopharmaceuticals, Inc. | Use of dermatan sulfates and/or desulfated heparins to treat or prevent heparinoid-induced autoimmune responses |
| US7939512B2 (en) | 2004-10-13 | 2011-05-10 | Laboratori Derivati Organici Spa | Multistep process for the physical depolymerization of heparin and products obtained therefrom |
| AU2009250803A1 (en) * | 2008-05-20 | 2009-11-26 | Crystal Clear Partnership | Separation of polysaccharides by charge density gradient |
| RU2014137454A (ru) * | 2012-02-17 | 2016-04-10 | Кимфлексор, С.Л. | Серебряные и золотые соли частично деполимеризованного гликозаминогликана |
| CN104884475B (zh) * | 2012-12-28 | 2017-11-07 | 杜邦营养生物科学有限公司 | 藻酸的解聚 |
| WO2020121179A1 (en) * | 2018-12-11 | 2020-06-18 | Universita' Degli Studi Di Salerno | Composition for the treatment of skin lesions |
| KR102240239B1 (ko) * | 2019-04-23 | 2021-04-14 | (주)티엠비 | 저분자량 히알루론산의 제조방법 및 이로부터 제조된 저분자량 히알루론산 |
| EP3997238A1 (en) | 2019-07-09 | 2022-05-18 | Optimvia, LLC | Methods for synthesizing anticoagulant polysaccharides |
| CN111040047A (zh) * | 2019-12-11 | 2020-04-21 | 东营天东制药有限公司 | 一种酶-超滤法精制低分子硫酸皮肤素的工艺、应用 |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE136572C (ko) * | 1902-12-05 | |||
| US3453194A (en) * | 1966-08-03 | 1969-07-01 | Dow Corning | Anticoagulant surfaces produced by radiation grafting heparin to a silicone substrate |
| US3766167A (en) * | 1971-03-26 | 1973-10-16 | Research Corp | Orally active anticoagulant |
| IT1075117B (it) * | 1977-02-14 | 1985-04-22 | Fedeli Gianfranco | Complesso polisaccaridico arterioso,processo per la sua preparazione e suo impiego in terapia umana |
| FR2440376A1 (fr) * | 1978-11-06 | 1980-05-30 | Choay Sa | Composition mucopolysaccharidique ayant une activite regulatrice de la coagulation, medicament la contenant et procede pour l'obtenir |
| CA1136620A (en) * | 1979-01-08 | 1982-11-30 | Ulf P.F. Lindahl | Heparin fragments having selective anticoagulation activity |
| IL61201A (en) * | 1979-10-05 | 1984-09-30 | Choay Sa | Oligosaccharides having no more than 8 saccharide moieties,their obtention from heparin and pharmaceutical compositions containing them |
| US4351938A (en) * | 1980-05-19 | 1982-09-28 | Riker Laboratories, Inc. | Anticoagulant substance |
| CA1171375A (en) * | 1980-09-15 | 1984-07-24 | Ulf P.F. Lindahl | Oligosaccharides having selective anticoagulation activity |
| FR2495935A1 (fr) * | 1980-12-15 | 1982-06-18 | Choay Sa | Fractions mucopolysaccharidiques possedant des proprietes biologiques, leur procede de preparation et leur application en tant que medicaments |
| EP0066908B1 (en) * | 1981-05-21 | 1985-08-28 | Akzo N.V. | New anti-thromboticum based on polysacharides, method for its preparation and pharmaceutical compositions |
| IT1195497B (it) * | 1983-03-08 | 1988-10-19 | Opocrin Spa | Procedimento per la preparazione di frazioni oligosaccaridiche dotate di proprieta' farmacologiche per degradazione chimica di eparina |
| DK196986D0 (da) * | 1986-04-30 | 1986-04-30 | Novo Industri As | Fremstilling af polysaccharider |
| US4788307A (en) * | 1986-04-30 | 1988-11-29 | Choay S.A. | Oligosaccharidic fractions devoid or practically devoid of antithrombotic activity |
-
1986
- 1986-11-24 IT IT8622434A patent/IT1213384B/it active
-
1987
- 1987-11-16 ES ES87116862T patent/ES2020993B3/es not_active Expired - Lifetime
- 1987-11-16 EP EP87116862A patent/EP0269937B1/en not_active Expired - Lifetime
- 1987-11-16 DE DE8787116862T patent/DE3768074D1/de not_active Expired - Fee Related
- 1987-11-16 US US07/120,953 patent/US4987222A/en not_active Expired - Lifetime
- 1987-11-16 AT AT87116862T patent/ATE60924T1/de not_active IP Right Cessation
- 1987-11-16 NO NO874777A patent/NO874777L/no unknown
- 1987-11-17 DK DK602387A patent/DK602387A/da not_active Application Discontinuation
- 1987-11-20 PT PT86191A patent/PT86191B/pt not_active IP Right Cessation
- 1987-11-23 CA CA000552481A patent/CA1305134C/en not_active Expired - Lifetime
- 1987-11-23 AU AU81609/87A patent/AU603622B2/en not_active Ceased
- 1987-11-24 FI FI875185A patent/FI88045C/fi not_active IP Right Cessation
- 1987-11-24 KR KR1019870013216A patent/KR880005936A/ko not_active Application Discontinuation
- 1987-11-24 JP JP62294255A patent/JPS63213502A/ja active Granted
-
1991
- 1991-03-27 GR GR91400383T patent/GR3001670T3/el unknown
Also Published As
| Publication number | Publication date |
|---|---|
| ATE60924T1 (de) | 1991-03-15 |
| EP0269937B1 (en) | 1991-02-20 |
| FI88045B (fi) | 1992-12-15 |
| NO874777L (no) | 1988-05-25 |
| GR3001670T3 (en) | 1992-11-23 |
| FI88045C (fi) | 1993-03-25 |
| AU603622B2 (en) | 1990-11-22 |
| AU8160987A (en) | 1988-05-26 |
| DE3768074D1 (de) | 1991-03-28 |
| IT1213384B (it) | 1989-12-20 |
| PT86191B (pt) | 1990-11-07 |
| JPS63213502A (ja) | 1988-09-06 |
| FI875185A0 (fi) | 1987-11-24 |
| FI875185A (fi) | 1988-05-25 |
| ES2020993B3 (es) | 1991-10-16 |
| PT86191A (en) | 1987-12-01 |
| NO874777D0 (no) | 1987-11-16 |
| EP0269937A3 (en) | 1989-03-08 |
| EP0269937A2 (en) | 1988-06-08 |
| CA1305134C (en) | 1992-07-14 |
| US4987222A (en) | 1991-01-22 |
| JPH0588881B2 (ko) | 1993-12-24 |
| DK602387D0 (da) | 1987-11-17 |
| DK602387A (da) | 1988-09-15 |
| IT8622434A0 (it) | 1986-11-24 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| KR880005936A (ko) | 저분자량 글루코스아미노글리칸의 조절된 제조방법 | |
| JPS63278901A (ja) | 通常の構造の低分子量のヘパリンとその製法並びに生物学的な応用 | |
| FI942095A0 (fi) | Puhdistettuja hepariinifraktioita, menetelmä niiden valmistamiseksi ja niitä sisältäviä farmaseuttisia koostumuksia | |
| ES2007422A6 (es) | Un metodo para modificar alginatos u otros compuestos que contienen acido uronico. | |
| ATE161273T1 (de) | Polysaccharidderivate von heparin, heparansulfate, ihre fraktionen und fragmente, verfahren zu deren herstellung und pharmazeutische zusammensetzungen, welche diese enthalten | |
| CN1161124C (zh) | 具有抗凝集/抗血栓形成作用的硫酸化低聚糖类化合物 | |
| ATE119547T1 (de) | Oligosaccharide mit antiatherosclerotischer wirkung. | |
| FI106034B (fi) | Menetelmä sulfatoitujen polysakkaridien terapeuttisesti käyttökelpoisen seoksen valmistamiseksi | |
| CN109575156B (zh) | 一种低分子肝素的纯化方法 | |
| KR910700269A (ko) | 신규 황산화 폴리사카라이드, 약학적으로 허용 가능한 그의 염, 이의 제조방법 및 유효성분으로서 이를 함유하는 약제 | |
| SE8802480D0 (sv) | Method of preparation of nucleic acid derivatives and method of preparation of medical composition containing the same | |
| DE3483801D1 (de) | Heparansulfat-fraktionen, ihre herstellung sowie sie enthaltende mittel. | |
| Brereton | Polymer-plastics technology and engineering volume 4: Edited by L. Naturman Marcel Dekker, New York, 1975, 249 pp. $32.50 | |
| Atkins | Heparin, structure, function and clinical implications: Edited by Ralph A. Bradshaw and Stanford Wessler Plenum Press, New York, 1975, 422 pp. $39.1 | |
| Huet et al. | Unfractionated heparin vs low molecular weight heparin fraction (LMWH): An experimental study during neurosurgery | |
| van Rijn et al. | Binding of heparin to endothelial cells |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| WITN | Application deemed withdrawn, e.g. because no request for examination was filed or no examination fee was paid |